Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises FAM in connection with the restructuring of Bergvik Skog and the formation of Kopparfors Skogar
Mandate

Vinge advises FAM in connection with the restructuring of Bergvik Skog and the formation of Kopparfors Skogar

May 31, 2019

FAM and other shareholders in Bergvik Skog AB have performed a restructuring of the ownership of Bergvik Skog whereupon, among other things, Bergvik Skog Väst AB has been divided up and one of FAM wholly‑owned subsidiaries, Kopparfors Skogar AB, has acquired through a subsidiary approximately 283 000 hectares of land in central Sweden. 

FAM was advised by Vinge, the team of which primarily consisted of Jonas Johansson, Joacim Rydergård, Carl Sander and Jesper Lindvall (Corporate/M&A), Assur Badur and Karolina Cohrs (Real Estate), Thomas Sjöberg (Environmental), Louise Brorsson Salomon (Financing) and Johan Wahlbom (Competition Law).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024